Discussion

• Fibroblast growth factor receptors are protein tyrosine kinases, consisting of 4 family member (FGFR1-4).¹
• FGFR signaling leads to activation of MAPK and PI3-K/Akt pathways.
• FGFR aberrations are present in approximately 20% of advanced urothelial carcinomas.^2,3
• Phase I study of pan FGFR inhibitor JNJ-42756493: 3 patients with heavily pretreated urothelial carcinoma and FGFR aberrations demonstrated partial responses.⁴
• Phase I study of selective FGFR 1-3 inhibitor BGJ398: Of 8 patients with FGFR3 mutated urothelial cancers treated at doses >= 100mg, 6 experienced stable disease or partial responses.⁵
• This patient’s case illustrates the potential utility of targeting pathogenic FGFR aberrations in urothelial cancers.
• This patient had exhausted standard cytotoxic therapies and subsequently derived a meaningful clinical benefit and 6 month progression free interval with the use of a FGFR inhibitor.
• Although FGFR inhibitors are not available for routine clinical use in early 2017, clinical development is ongoing.